-
公开(公告)号：US20210177986A1
公开(公告)日：2021-06-17
申请号：US17151898
申请日：2021-01-19
Applicant: University of Utah Research Foundation
Inventor： Youngwook Won , David A. Bull , Kwangsuk Lim
IPC: A61K47/68 , C07K16/32 , A61K9/00 , A61K31/27 , A61K31/337
Abstract: Disclosed herein, is a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains, and one or more therapeutic agents, wherein the therapeutic agent is allosterically bound to the biological binding domain. Also described herein, are methods of incorporating a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains that captures the therapeutic agent without the formation of a chemical bond, and one or more therapeutic agents physiologically acceptable compositions including them; and methods of administering the bi-functional allosteric protein-drug molecule to patients for the treatment of cancer.
-
公开(公告)号：US20170368196A1
公开(公告)日：2017-12-28
申请号：US15534948
申请日：2015-12-11
Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventor： Youngwook Won , David A. Bull , Kwangsuk Lim
IPC: A61K47/68 , A61K31/27 , A61K9/00 , A61K31/337
CPC classification number: A61K47/6855 , A61K9/0019 , A61K31/27 , A61K31/337 , A61K47/6801 , A61K47/6803 , A61K47/6849 , A61K47/6879 , A61K47/6889 , C07K16/32 , C07K2317/622 , C07K2319/33
Abstract: Disclosed herein, is a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains, and one or more therapeutic agents, wherein the therapeutic agent is allosterically bound to the biological binding domain. Also described herein, are methods of incorporating a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains that captures the therapeutic agent without the formation of a chemical bond, and one or more therapeutic agents; physiologically acceptable compositions including them; and methods of administering the bi-functional allosteric protein-drug molecule to patients for the treatment of cancer.
-
公开(公告)号：US12180300B2
公开(公告)日：2024-12-31
申请号：US17277828
申请日：2019-09-20
Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA , UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventor： Youngwook Won , David A. Bull , Daniel Yongwon Lee
Abstract: Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
-
公开(公告)号：US10898582B2
公开(公告)日：2021-01-26
申请号：US15534948
申请日：2015-12-11
Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventor： Youngwook Won , David A. Bull , Kwangsuk Lim
IPC: A61K47/68 , C07K16/32 , A61K9/00 , A61K31/27 , A61K31/337
Abstract: Disclosed herein, is a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains, and one or more therapeutic agents, wherein the therapeutic agent is allosterically bound to the biological binding domain. Also described herein, are methods of incorporating a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains that captures the therapeutic agent without the formation of a chemical bond, and one or more therapeutic agents; physiologically acceptable compositions including them; and methods of administering the bi-functional allosteric protein-drug molecule to patients for the treatment of cancer.
-
-
-
Search Results
4
records
(took 0.016 seconds)
